Orange Book product · Brand (NDA)
VASOPRESSIN IN SODIUM CHLORIDE 0.9%
VASOPRESSIN
At a glance
Sep 29, 2023
Approved
Brand (NDA)
Application
Not listed
TE code
1
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Sep 29, 2023
2 yr 9 mo ago
Today
Patent 12447190 expires
Listed drug product patent expiration.
Sep 27, 2044
in 18 yr 7 mo
Pharmaceutical detail
Active ingredient
VASOPRESSIN
Strength
20UNITS/100ML (0.2UNITS/ML)
Dosage form
SOLUTION
Route
INTRAVENOUS
TE code
Not listed
Application
NDA 217569
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2024VASOPRESSIN IN SODIUM CHLORIDE 0.9%Brand (NDA)
NDA 217766 · LONG GROVE PHARMS
- 2020VASOPRESSINBrand (NDA)
NDA 212593 · AM REGENT
- 2014VASOSTRICTBrand (NDA)
NDA 204485 · PH HEALTH
- 2026VASOPRESSINGeneric (ANDA)
ANDA 212068 · SANDOZ
- 2026VASOPRESSINGeneric (ANDA)
ANDA 212069 · SANDOZ
- 2024VASOPRESSINGeneric (ANDA)
ANDA 213988 · DR REDDYS
- 2024VASOPRESSINGeneric (ANDA)
ANDA 216963 · GLAND
- 2023VASOPRESSINGeneric (ANDA)
ANDA 217987 · CIPLA
- 2023VASOPRESSINGeneric (ANDA)
ANDA 213206 · FRESENIUS KABI USA
- 2022VASOPRESSINGeneric (ANDA)
ANDA 214314 · EUGIA PHARMA
- 2022VASOPRESSINGeneric (ANDA)
ANDA 212944 · AMNEAL
- 2022VASOPRESSINGeneric (ANDA)
ANDA 211857 · AMPHASTAR PHARMS INC
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 12447190 | Sep 27, 2044 | in 18 yr 7 mo | Product |

